QL2109

DRUG4 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Malignant Plasma Cell NeoplasmsMultiple MyelomaTumor

Phase 1

A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

RecruitingNCT06371534

Qilu Pharmaceutical Co., Ltd.Tumor

Start: 2024-04-12End: 2025-04-30Target: 228Updated: 2025-02-11

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

Not yet recruitingNCT07400744

Qilu Pharmaceutical Co., Ltd.Multiple Myeloma

Start: 2026-03-01End: 2026-10-01Target: 102Updated: 2026-02-10

Phase 2

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

Not yet recruitingNCT07560449

Qilu Pharmaceutical Co., Ltd.Malignant Plasma Cell Neoplasms

Start: 2026-06-01End: 2030-06-01Target: 162Updated: 2026-05-01

Phase 3

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

Not yet recruitingNCT06742138

Qilu Pharmaceutical Co., Ltd.Multiple Myeloma

Start: 2025-01-31End: 2028-12-31Target: 284Updated: 2024-12-19